{"id":123524,"date":"2026-01-14T23:57:08","date_gmt":"2026-01-14T23:57:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-tx\/123524\/"},"modified":"2026-01-14T23:57:08","modified_gmt":"2026-01-14T23:57:08","slug":"biotech-co-gradalis-names-former-novartis-exec-as-its-new-ceo-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-tx\/123524\/","title":{"rendered":"Biotech Co. Gradalis Names Former Novartis Exec as\u00a0Its New\u00a0CEO \u00bb Dallas Innovates"},"content":{"rendered":"

\"\"<\/p>\n

Gradalis CEO Steven Weinstein [Photo: Gradalis]<\/p>\n

Carrollton-based Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, has named Steven D. Weinstein as its new chief executive officer.<\/p>\n

With more than two decades of experience in life sciences leadership, venture capital, and company building, Weinstein brings a track record of guiding innovative healthcare organizations from early-stage development through commercialization. He has extensive experience in strategic financing, clinical development, and operational leadership, Gradalis said.<\/p>\n

\u201cSteve\u2019s deep expertise in oncology, combined with his ability to translate breakthrough science into successful businesses, makes him the ideal leader for Gradalis as we advance our immunotherapy platform,\u201d David Shanahan, Gradalis\u2019 co-founder and chairman, said in a statement. \u201cHis vision and experience will accelerate our mission to deliver transformative treatments to patients with cancer.\u201d<\/p>\n

VC investing and entrepreneurship<\/p>\n

Weinstein brings more than 20 years as a life science venture capital investor and company builder.<\/p>\n

As managing director of the Novartis Venture Fund for 12 years, he was actively engaged in all investment decisions across the $800M global portfolio, Gradalis said. Prior to Novartis, Weinstein was part of the life science team at Prism Venture Partners, a $1.25 billion family of funds. He began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds.<\/p>\n

More recently, Weinstein was CEO of Gregor Diagnostics, where he built a leadership team and advanced the R&D and clinical strategy for a novel prostate cancer diagnostic. He also served as chairman of SpectraWAVE, an interventional cardiology imaging platform that recently announced its acquisition by Philips, from R&D to commercial-stage, and was interim-CEO of Rox Medical (cardiovascular).<\/p>\n

\u201cI\u2019m honored to join Gradalis at this pivotal moment,\u201d Weinstein said. \u201cRecurrent and resistant solid tumor cancers remain among the greatest challenges in oncology. Gradalis\u2019 strong mechanistic understanding and clear biomarker-driven patient stratification enables a personalized immunotherapy approach with tremendous promise. I look forward to working with this talented team to expand access to our innovative therapies and improve outcomes for patients.\u201d<\/p>\n

Supporting life science innovation<\/p>\n

Weinstein is a member of the Product Development Review Council for the Cancer Prevention and Research Institute of Texas (CPRIT) and serves as an advisor to the UPMC Enterprises Fund, an Expert-in-Residence to Digitalis Commons supporting ARPA-H\u2019s innovation initiative, and as an advisor to the Rockefeller Neuroscience Institute.<\/p>\n

He has served as a consultant to Genentech Neuroscience and the American Academy of Ophthalmology and as a member of the Innovation Advisory Board of Mass General Brigham Healthcare.<\/p>\n

Gradalis is a clinical-stage biotechnology company advancing Vigil\u00ae, a Phase 3\u2013ready, personalized immunotherapy built on its proprietary bi-shRNA platform. Vigil harnesses the patient\u2019s own tumor clonal neoantigens to activate the immune system and deliver lasting anti-tumor responses.<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n

\t\"\"<\/a><\/p>\n

The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.<\/p>\n

\t\"\"<\/a><\/p>\n

A scientific footnote from 1922 is now a potential key to treating diabetic nerve pain, a chronic and widespread condition with few effective options. The new study wouldn’t have happened without the nonprofit Southwest Transplant Alliance, says UT Dallas neuroscientist Ted Price, who credits the group with making the research possible.<\/p>\n

\t\"\"<\/a><\/p>\n

Precision Care Companion (PCC) is a consortium of industry experts, led by McKesson, designed to help healthcare practices improve patient care.<\/p>\n

The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.<\/p>\n

\t\"Anthony<\/a><\/p>\n

Anthony Milonas brings more than two decades of experience leading and scaling multi-site healthcare organizations across North America.<\/p>\n","protected":false},"excerpt":{"rendered":"Gradalis CEO Steven Weinstein [Photo: Gradalis] Carrollton-based Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, has…\n","protected":false},"author":2,"featured_media":123525,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[53559,53560,53561,19882,53562,53563,53564,53565,53566,53567,160,162,161,53568,53569,53570],"class_list":["post-123524","post","type-post","status-publish","format-standard","has-post-thumbnail","category-plano","tag-american-academy-of-ophthalmology","tag-arpa-hs-innovation-initiative","tag-clinical-stage-oncology-biopharmaceutical-firm","tag-cprit","tag-digitalis-commons","tag-genentech-neuroscience","tag-gradalis","tag-mass-general-brigham-healthcare","tag-novartis","tag-oncology-novel-therapeutics","tag-plano","tag-plano-headlines","tag-plano-news","tag-rockefeller-neuroscience-institute","tag-steven-weinstein","tag-upmc-enterprises-fund"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/123524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=123524"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/123524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/123525"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=123524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=123524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=123524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}